These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33789880)

  • 1. Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy.
    Ferdinandus J; Metzenmacher M; Kessler L; Umutlu L; Aigner C; Karl KO; Grünwald V; Eberhardt W; Fendler WP; Herrmann K; Faehling M; Christoph DC
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
    Ferdinandus J; Zaremba A; Zimmer L; Umutlu L; Seifert R; Barbato F; Ugurel S; Chorti E; Grünwald V; Herrmann K; Schadendorf D; Fendler WP; Livingstone E
    Cancer Imaging; 2022 Feb; 22(1):11. PubMed ID: 35123578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
    Bilger G; Girard N; Doubre H; Levra MG; Giroux-Leprieur E; Giraud F; Decroisette C; Carton M; Massiani MA
    Cancer Immunol Immunother; 2022 Jul; 71(7):1719-1731. PubMed ID: 34821950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
    Castello A; Toschi L; Rossi S; Mazziotti E; Lopci E
    J Cancer Res Clin Oncol; 2020 May; 146(5):1235-1243. PubMed ID: 32048008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
    J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of integrated
    Umeda Y; Morikawa M; Anzai M; Ameshima S; Kadowaki M; Waseda Y; Shigemi H; Tsujikawa T; Kiyono Y; Okazawa H; Ishizuka T
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study.
    Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Eisenhut M; Pan L; Haberkorn U; Strauss LG
    Mol Imaging Biol; 2007; 9(5):308-17. PubMed ID: 17623254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
    Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
    Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure.
    Mac Manus MP; Hicks RJ; Matthews JP; Wirth A; Rischin D; Ball DL
    Lung Cancer; 2005 Jul; 49(1):95-108. PubMed ID: 15949595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
    Valentinuzzi D; Vrankar M; Boc N; Ahac V; Zupancic Z; Unk M; Skalic K; Zagar I; Studen A; Simoncic U; Eickhoff J; Jeraj R
    Radiol Oncol; 2020 Jul; 54(3):285-294. PubMed ID: 32726293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor metabolic volume by
    Yamaguchi O; Kaira K; Hashimoto K; Mouri A; Shiono A; Miura Y; Murayama Y; Kobayashi K; Kagamu H; Kuji I
    Sci Rep; 2020 Sep; 10(1):14990. PubMed ID: 32929123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
    Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
    Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence.
    Dudnik E; Moskovitz M; Agbarya A; Gottfried T; Shochat T; Urban D; Zer A; Rotem O; Moore A; Yust S; Peled N; Wollner M; Bar J;
    Int J Cancer; 2021 Mar; 148(5):1183-1191. PubMed ID: 32875571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
    Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM
    Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.